Increased activity and expression of tyrosine hydroxylase in the rat substantia nigra after chronic treatment with nomifensine

Molecular Pharmacology

Volumn 52, Issue 4, 1997, Pages 641-647

  Rodríguez Gómez, José A ^a   Romero Ramos, Marina ^a   Vizuete, María L ^a   Venero, José L ^a   Cano, Josefina ^a   Machado, Alberto ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

NOMIFENSINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINE UPTAKE; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; ENZYME ACTIVITY; GENE EXPRESSION; IN SITU HYBRIDIZATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; TRANSCRIPTION REGULATION;

EID: 1842336267     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.52.4.641     Document Type: Article

References (42)

1. Ehringer, H., and O. Hornykiewicz. Verteilung von noradrenalin und dopamin (3-hydroxytyramin) im gehirn des menschen und ihr verhalten bei erkrankungen des extrapyramidalen system. Klin. Wochenschr. 38: 1236-1239 (1960).
2. Kopin, I. J. The pharmacology of Parkinson's disease therapy: an update. Annu. Rev. Toxicol. 32:467-495 (1993).
3. Berry, M. D., A. V. Jourio, and I. A. Paterson. Possible mechanisms of action of (-)-deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders. Prog. Neurobiol. (Oxf). 44:141-161 (1994).
4. Schulzer, M., E. Mak, and D. B. Calue. The anti-Parkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann. Neurol. 32:795-798 (1992).
5. Gerlach, M., M. B. Youdim, and P. Riederer. Pharmacology of selegiline. Neurology 47:137-145 (1996).
6. de la Cruz, C. P., E. Revilla, and V. Steffen, J. A. Rodríguez-Gómez, J. Cano, and A. Machado. Protection of the aged substantia nigra of the rat against oxidative damage by (-)-deprenyl. Br. J. Pharmacol. 117:1756-1760 (1996).
7. Rodríguez-Gómez, J. A., J. L. Venero, M. L. Vizuete, J. Cano, and A. Machado. Deprenyl induces the tyrosine hydroxylase enzyme in the rat dopaminergic nigrostriatal system. Mol. Brain Res. 46:31-38 (1997).
8. Revuelta, M., J. L. Venero, A. Machado, and J. Cano. Deprenyl induces GFAP immunoreactivity in the intact and injured dopaminergic nigrostriatal system but fails to counteract axotomy-induced degeneratives changes. Glia., in press.
9. Levitt, M., S. Spector, A. Sjoerdsma, and S. Udenfriend. Elucidation of the rate limiting step in norephinephrine biosynthesis in the perfused guineapig heart. J. Pharmacol. Exp. Ther. 145:1-7 (1965).
10. Bernheimer, H., W. Birkmayer, O. Hornykiewicz, K. Jellinger, and F. Seitelberger. Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlation. J. Neurol. Sci. 20:415-155 (1973).
11. Knoll, J. R. (-)-deprenyl (selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron. J. Neural Transm. 25:45-66 (1987).
12. Vrana, S. L., K. E. Vrana, T. R. Koves, J. E. Smith, and S. I. Dworkin. Chronic cocaine administration increases CNS tyrosine hydroxylase enzyme activity and mRNA levels and tryptophan hydroxylase enzyme activity levels. J. Neurochem. 61:2262-2268 (1993).
13. Giros, B., M. Jaber, S. R. Jones, R. M. Wightman, and M. Caron. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature (Lond.) 379:606-612 (1996).
14. Paxinos, G., and C. Watson. The Rat Brain in Stereotaxic Coordinates. Academic Press, New York (1986).
15. Venero, J. L., M. Santiago, A. Machado, and J. Cano. Determination of monoamines and both forms of monoamine oxidase in the rats substantia nigra during postnatal development. Life Sci. 45:1277-1283 (1989).
16. 3H)tyrosine by charcoal. Life Sci. 39:2185-2189 (1986).
17. 4. Nature (Lond.) 227:680-685 (1970).
18. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-275 (1951).
19. Passinetti, G. M., D. J. Morgan, S. A. Johnson, S. P. Lerner, M. A. Myers, J. Poirier, and C. E. Finch. Combined in situ hybridization and immunocytochemistry in the assay of pharmacological effects on tyrosine hydroxylase mRNA concentration. Pharmacol. Res. 21:299-311 (1989).
20. Lewis, E. J., A. W. Tank, N. Weiner, and D. M. Chikaraishi. Regulation of tyrosine hydroxylase mRNA by glucocorticoid and cyclic AMP in a rat pheochromocytoma cell line. J. Biol. Chem. 258:14632-14637 (1983).
21. Grima, B., A. Lamoroux, F. Blanot, N. Faucon-Biguet, and J. Mallet. Complete coding sequence of a rat tyrosine hydroxylase mRNA. Proc. Nat. Acad. Sci. USA 82:617-622 (1985).
22. Schacht, U., and W. Heptner. Effect of nomifensine (Hoe 984), a new antidepressant, on uptake noradrenaline and serotonin and on release of noradrenaline in rat brain synaptosomes. Biochem. Pharmacol. 23:3413-3422 (1975).
23. Carboni. E., A. Imperato, L. Perenazzi, and G. DiChiara. Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats. Neuroscience 28:653-661 (1989).
24. 3H]dopamine from rat striatal slices. Biochem. Pharmacol. 92:243-248 (1983).
25. Soares-da-Silva, P., and M. C. Garrett. A kinetic study of the rate of formation of dopamine, 3,4-dihydroxiphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the brain of the rat: implications for the origin of DOPAC. Neuropharmacology 29:869-874 (1990).
26. Kopin, I. J. Catecholamine metabolism: basic aspects and clinical significance. Pharmacol. Rev. 37:333-364 (1985).
27. Wodd, P. L., and C. A. Altar. Dopamine release in vivo from nigrostriatal, mesolimbic, and mesocortical neurons: utility of 3-methoxytiramine measurements. Pharmacol. Rev. 40:163-187 (1988).
28. Alburges, M. E, and J. K. Wamsley. Effects on monoamine levels in rat CNS after chronic administration of cocaine. Invest. Clin. 34:181-182 (1993).
29. 2 receptor in the rat brain by in situ hybridization histochemistry. Proc. Nat. Acad. Sci. USA 86:8560-8564 (1989).
30. Studer, A., and W. Schultz. The cathecolamine uptake inhibitor nomifensine depresses impulse activity of dopamine neurons in mouse substantia nigra. Neurosci. Lett. 80:207-212 (1987).
31. Santiago, M., and B. H. Westerink. Characterization and pharmacological responsiveness of dopamine release recorded by microdialysis in the substantia nigra of conscious rats. J. Neurochem. 57:738-747 (1991).
32. Heinonen, E. H., and R. Lammintausta. A review of the pharmacology of selegiline. Acta. Neurol. Scand. 136:44-59 (1991).
33. Vrana, S. A. L., A. J. Azzaro, and K. E. Vrana. Chronic selegiline administration transiently decreases tyrosine hydroxylase activity and mRNA in the rat nigrostriatal pathway. Mol. Pharmacol. 41:839-844 (1992).
34. Knoll, J. The facilitation of dopaminergic activity in the aged brain by deprenyl: a proposal for a strategy to improve the quality of life in senescence. Mech. Ageing Dev. 30:109-122. (1985).
35. Gropetti, A., and A. M. DiGulio. Cocaine and its effects on biogenic amines, in Frontiers in Cathecolamine Research (E. Usdin and S. Snyder, eds.). Pergamon Press, New York, 242-253 (1976).
36. Ritz, M. C., R. J. Lamb, S. R. Goldberg, and M. J. Kuhar. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science (Washington D. C.) 237:1219-1223 (1987).
37. Nakahara, D., H. Hashiguti, N. Kaneda, T. Sasaoka, and T. Nagatsu. Normalization of TH activity in vivo in the striatum of transgenic mice carrying human TH gene: a microdialysis study. Neurosci. Lett. 158:44-46 (1993).
38. Kiuchi, K., N. Kaneda, T. Sasaoka, H. Hidaka, and T. Nagatsu. Regulatory mechanism of dopamine biosynthesis in the striatum of transgenic mice carrying human TH gene. Neurosci. Lett. 151:55-58 (1993).
39. Romero-Ramos, M., J. A. Rodríguez-Gómez, J. L. Venero, J. Cano, and M. Machado. Chronic inhibition of the high affinity dopamine-uptake system increases oxidative damage to proteins in the aged rat substantia nigra. Free Radical Biol. Med. 23:1-7 (1997).
40. May, T., and M. Sugawa. Altered dopamine receptor mediated signal transmission in the striatum of aged rats. Brain Res. 604:106-111 (1993).
41. Mesco, E. R., S. G. Carlson, J. A. Joseph, and G. S. Roth. Decreased striatal D2 dopamine receptor mRNA synthesis during aging. Mol. Brain Res. 17:160-162 (1993).
42. Undie, A. S., and E. Friedman. Aging-induced decrease in dopaminergic-stimulated phosphoinositide metabolism in rat brain. Neurobiol. Aging 13:505-511 (1992).